CTLA4 and cancer: Cancer immunotherapy has advanced rapidly with the inclusion of numerous ICBs approved against specific targets, such as ipilimumab, an inhibitor of CTLA-4, and nivolumab and pembrolizumab, PD-1 inhibitors [3,36,37].